Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 10
Submit an article Journal homepage
65
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Bing-Neel syndrome coexisting with oligodendroglioma

Livia Donzellia Hematology Unit, Department of Translational and Precision Medicine, Sapienza University, Rome, ItalyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-6926-3648
ORCID Icon,
Clara Minottia Hematology Unit, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy
,
Giovanni Fernando Torellia Hematology Unit, Department of Translational and Precision Medicine, Sapienza University, Rome, ItalyORCID Iconhttps://orcid.org/0000-0002-3920-5586
ORCID Icon,
Claudio Cartonia Hematology Unit, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy
,
Cristina Luisea Hematology Unit, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy
,
Alice Di Roccoa Hematology Unit, Department of Translational and Precision Medicine, Sapienza University, Rome, ItalyORCID Iconhttps://orcid.org/0000-0003-0985-9623
ORCID Icon,
Luigi Petruccia Hematology Unit, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy
,
Arianna Di Napolib Pathology Unit, Department of Clinical and Molecular Medicine, Sant'Andrea Hospital, Sapienza University, Rome, ItalyORCID Iconhttps://orcid.org/0000-0002-3159-5380
ORCID Icon &
Maurizio Martellia Hematology Unit, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy
 show all
Pages 2511-2514 | Received 21 Feb 2022, Accepted 07 May 2022, Published online: 19 May 2022

References

  • BING JENS, NEEL AV. Two cases of hyperglobulinaemia with affection of the central nervous system on a toxi-infectious basis. Acta Med Scand. 2009;88(5-6):492–506.
  • Minnema MC, Kimby E, D'Sa S, et al. Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome. Haematologica. 2017;102(1):43–51.
  • Simon L, Fitsiori A, Lemal R, et al. Bing-Neel syndrome, a rare complication of Waldenström macroglobulinemia: analysis of 44 cases and review of the literature. A study on behalf of the French Innovative Leukemia Organization (FILO). Haematologica. 2015;100(12):1587–1594.
  • Castillo JJ, D'Sa S, Lunn MP, et al. Central nervous system involvement by Waldenström macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study. Br J Haematol. 2016;172(5):709–715.
  • Poulain S, Boyle EM, Roumier C, et al. MYD88 L265P mutation contributes to the diagnosis of Bing Neel syndrome. Br J Haematol. 2014;167(4):506–513.
  • Varettoni M, Arcaini L, Zibellini S, et al. Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom’s macroglobulinemia and related lymphoid neoplasms. Blood. 2013;121(13):2522–2528.
  • Mason C, Savona S, Rini JN, et al. Ibrutinib penetrates the blood brain barrier and shows efficacy in the therapy of Bing Neel syndrome. Br J Haematol. 2017;179(2):339–341.
  • Boudin L, Patient M, Roméo E, et al. Efficacy of ibrutinib as first-line treatment of tumoral Bing-Neel syndrome. Leuk Lymphoma. 2018;59(11):2746–2748.
  • Castillo JJ, Itchaki G, Paludo J, et al. Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study. Blood. 2019;133(4):299–305.
  • Ferreri AJ, Cwynarski K, Pulczynski E, et al. International Extranodal Lymphoma Study Group (IELSG). Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol. 2016;3(5):e217–e227.
  • Ferreri AJM, Calimeri T, Lopedote P, et al. MYD88 L265P mutation and interleukin-10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study. Br J Haematol. 2021;193(3):497–505.
  • Ita MI, Wang JH, Toulouse A, et al. The utility of plasma circulating cell-free messenger RNA as a biomarker of glioma: a pilot study. Acta Neurochir. 2022;164(3):723–735.
  • Guo Q, Xiao X, Zhang J. MYD88 is a potential prognostic gene and immune signature of tumor microenvironment for gliomas. Front Oncol. 2021;11:654388.
  • Castillo JJ, Treon SP. How we manage Bing-Neel syndrome. Br J Haematol. 2019;187(3):277–285.
  • Treon SP, Xu L, Hunter Z. MYD88 mutations and response to ibrutinib in Waldenström’s macroglobulinemia. N Engl J Med. 2015;373(6):584–586.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.